CY1112368T1 - Συνδυασμοι θεραπευτικων παραγοντων για την αγωγη καρκινου - Google Patents

Συνδυασμοι θεραπευτικων παραγοντων για την αγωγη καρκινου

Info

Publication number
CY1112368T1
CY1112368T1 CY20121100074T CY121100074T CY1112368T1 CY 1112368 T1 CY1112368 T1 CY 1112368T1 CY 20121100074 T CY20121100074 T CY 20121100074T CY 121100074 T CY121100074 T CY 121100074T CY 1112368 T1 CY1112368 T1 CY 1112368T1
Authority
CY
Cyprus
Prior art keywords
inhibitor
kinase inhibitor
combinations
therapeutic agents
education
Prior art date
Application number
CY20121100074T
Other languages
Greek (el)
English (en)
Inventor
Sara Zaknoen
Margaret Ma Woo
Richard William Versace
Claudio Pisano
Loredana Vesci
Original Assignee
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36463409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112368(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. filed Critical Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.
Publication of CY1112368T1 publication Critical patent/CY1112368T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CY20121100074T 2004-12-15 2012-01-20 Συνδυασμοι θεραπευτικων παραγοντων για την αγωγη καρκινου CY1112368T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63643904P 2004-12-15 2004-12-15
EP05853820A EP1827437B1 (en) 2004-12-15 2005-12-13 Combinations of therapeutic agents for treating cancer

Publications (1)

Publication Number Publication Date
CY1112368T1 true CY1112368T1 (el) 2015-12-09

Family

ID=36463409

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121100074T CY1112368T1 (el) 2004-12-15 2012-01-20 Συνδυασμοι θεραπευτικων παραγοντων για την αγωγη καρκινου

Country Status (26)

Country Link
US (1) US8975248B2 (cg-RX-API-DMAC7.html)
EP (1) EP1827437B1 (cg-RX-API-DMAC7.html)
JP (1) JP5345323B2 (cg-RX-API-DMAC7.html)
KR (1) KR101367516B1 (cg-RX-API-DMAC7.html)
CN (1) CN101080227B (cg-RX-API-DMAC7.html)
AT (1) ATE531371T1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316652B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0515774A (cg-RX-API-DMAC7.html)
CA (1) CA2589521C (cg-RX-API-DMAC7.html)
CY (1) CY1112368T1 (cg-RX-API-DMAC7.html)
DK (1) DK1827437T3 (cg-RX-API-DMAC7.html)
ES (1) ES2374828T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20110960T1 (cg-RX-API-DMAC7.html)
IL (1) IL183595A0 (cg-RX-API-DMAC7.html)
MA (1) MA29096B1 (cg-RX-API-DMAC7.html)
MX (1) MX2007007212A (cg-RX-API-DMAC7.html)
NO (1) NO20073552L (cg-RX-API-DMAC7.html)
NZ (1) NZ555370A (cg-RX-API-DMAC7.html)
PL (1) PL1827437T3 (cg-RX-API-DMAC7.html)
PT (1) PT1827437E (cg-RX-API-DMAC7.html)
RU (1) RU2400232C2 (cg-RX-API-DMAC7.html)
SI (1) SI1827437T1 (cg-RX-API-DMAC7.html)
TN (1) TNSN07224A1 (cg-RX-API-DMAC7.html)
TW (1) TW200628151A (cg-RX-API-DMAC7.html)
WO (1) WO2006065780A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200704701B (cg-RX-API-DMAC7.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140070676A (ko) 2002-09-06 2014-06-10 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
ES2374828T3 (es) 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
WO2007014335A2 (en) * 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
PT2275103E (pt) 2005-11-21 2014-07-24 Novartis Ag Inibidores de mtor para o tratamento de tumores endócrinos
WO2007094026A1 (en) * 2006-02-17 2007-08-23 Paolo La Colla Prophylactic and/or therapeutic treatment of proliferative and conformational diseases
RU2452492C2 (ru) * 2006-04-05 2012-06-10 Новартис Аг КОМБИНАЦИИ, ВКЛЮЧАЮЩИЕ ИНГИБИТОРЫ Bcr-Abl/c-Kit/PDGF-R TK, ДЛЯ ЛЕЧЕНИЯ РАКА
CA2645633A1 (en) * 2006-04-05 2007-11-01 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101415411A (zh) * 2006-04-05 2009-04-22 诺瓦提斯公司 用于治疗癌症的治疗剂组合
US20080176958A1 (en) 2007-01-24 2008-07-24 Insert Therapeutics, Inc. Cyclodextrin-based polymers for therapeutics delivery
EP2060565A1 (en) * 2007-11-16 2009-05-20 4Sc Ag Novel bifunctional compounds which inhibit protein kinases and histone deacetylases
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CN101837129B (zh) * 2009-03-19 2012-12-12 鼎泓国际投资(香港)有限公司 含cMet抑制剂、HDAC抑制剂与EGFR酪氨酸激酶抑制剂的药物组合物及其应用
US20120114658A1 (en) * 2009-09-15 2012-05-10 John Ryan Treatment of cancer
CN102946879B (zh) * 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
EP2786755A3 (en) 2010-11-12 2014-10-29 Pharma Mar S.A. Combination therapy with an antitumor alkaloid
CN102731516B (zh) * 2011-04-07 2014-07-02 宁波天衡药业股份有限公司 一类具有抗肿瘤活性的喜树碱衍生物
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
KR102359214B1 (ko) 2014-04-04 2022-02-07 델 마 파마슈티컬스 폐의 비소세포 암종 및 난소암을 치료하기 위한 디안하이드로갈락티톨 및 이의 유사체 또는 유도체
PT3127545T (pt) * 2014-04-04 2020-07-20 Taiho Pharmaceutical Co Ltd Fármaco antitumoral que contém composto de taxano e potenciador de efeito antitumoral
EP3307263A4 (en) 2015-06-15 2019-02-13 NewSouth Innovations Pty Limited PHARMACEUTICAL COMBINATIONS OF ORGANO ARSENOXIDE COMPOUNDS AND MTOR HAZARDS
CN107951888A (zh) * 2017-12-19 2018-04-24 天津科技大学 阿法替尼与10-羟基喜树碱的药物组合及其应用
CN109091480A (zh) * 2018-09-19 2018-12-28 天津科技大学 癌组合物10-羟基喜树碱和克唑替尼治疗肺癌及用途
BR112021011894A2 (pt) * 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
CN111789903A (zh) * 2019-04-08 2020-10-20 石小和 治疗尿道癌的药物组合物及其制备方法
CA3158733A1 (en) 2019-11-21 2021-05-27 Pilar Calvo Methods of treating small cell lung cancer with lurbinectedin formulations
CN120695174A (zh) * 2021-07-01 2025-09-26 江苏先声生物制药有限公司 抗人vegf抗体与化药联用在制备治疗卵巢癌的药物中的应用
WO2023165603A1 (en) * 2022-03-03 2023-09-07 Zai Lab (Shanghai) Co., Ltd. Dna-pk inhibitor and combination use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08169825A (ja) * 1994-12-15 1996-07-02 Tanaka Kikinzoku Kogyo Kk 抗癌剤の併用投与方法及び併用可能な抗癌剤
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US7105492B2 (en) * 1999-03-09 2006-09-12 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
DK1044977T3 (da) * 1999-03-09 2002-07-08 Sigma Tau Ind Farmaceuti Camptothecinderivater med antitumoraktivitet
GB0119249D0 (en) * 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US20050038048A1 (en) 2001-10-29 2005-02-17 Ball Howard Ashley Use of 7h-pyrrollo{2,3-d}pyrimidine derivatives in the treatment of solid tumor diseases
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
HRP20050115A2 (en) * 2002-07-11 2005-10-31 Combinatorx Combinations of drugs for the treatment of neoplasms
WO2004103358A2 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
CA2569277A1 (en) * 2004-06-04 2005-12-15 Pfizer Products Inc. Method for treating abnormal cell growth
ES2374828T3 (es) 2004-12-15 2012-02-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combinaciones de agentes terapéuticos para el tratamiento del cáncer.
JP4702322B2 (ja) 2006-12-14 2011-06-15 トヨタ自動車株式会社 内燃機関の制御装置

Also Published As

Publication number Publication date
TNSN07224A1 (en) 2008-11-21
ES2374828T3 (es) 2012-02-22
CN101080227A (zh) 2007-11-28
IL183595A0 (en) 2007-10-31
CN101080227B (zh) 2011-08-31
US20100028338A1 (en) 2010-02-04
MX2007007212A (es) 2007-11-07
CA2589521C (en) 2014-04-01
PL1827437T3 (pl) 2013-06-28
BRPI0515774A (pt) 2008-08-05
PT1827437E (pt) 2012-01-12
EP1827437B1 (en) 2011-11-02
KR20070091286A (ko) 2007-09-10
US8975248B2 (en) 2015-03-10
WO2006065780A3 (en) 2006-08-17
HRP20110960T1 (hr) 2012-01-31
MA29096B1 (fr) 2007-12-03
NZ555370A (en) 2010-03-26
AU2005316652B2 (en) 2009-07-23
SI1827437T1 (sl) 2012-02-29
WO2006065780A2 (en) 2006-06-22
RU2007126978A (ru) 2009-01-27
JP2008524225A (ja) 2008-07-10
NO20073552L (no) 2007-09-12
AU2005316652A1 (en) 2006-06-22
TW200628151A (en) 2006-08-16
ZA200704701B (en) 2008-09-25
EP1827437A2 (en) 2007-09-05
RU2400232C2 (ru) 2010-09-27
JP5345323B2 (ja) 2013-11-20
KR101367516B1 (ko) 2014-02-27
ATE531371T1 (de) 2011-11-15
CA2589521A1 (en) 2006-06-22
DK1827437T3 (da) 2012-02-13

Similar Documents

Publication Publication Date Title
TNSN07224A1 (en) Combinations of therapeutic agents for treating cancer
Ferrario et al. Avastin enhances photodynamic therapy treatment of Kaposi's sarcoma in a mouse tumor model
ES2654623T3 (es) Inhibidores bivalentes de proteínas IAP y métodos terapéuticos que los usan
MXPA06003163A (es) Combinacion de un inhibidor de receptor de vegf con un agente quimioterapeutico.
MXPA05013642A (es) Composicion de un antagonista de vegf y un agente antiproliferativo y su uso para el tratamiento de cancer.
RU2008152435A (ru) Композиции и способы регулирования развития сосудов
CY1118564T1 (el) Σχημα πολλαπλων-μεταβλητων δοσεων για αντιμετωπιση νοσου του crohn kai ελκωδους κολιτιδας
CY1115782T1 (el) Φαρμακευτικες συνθεσεις για θεραπεια καρκινου
NO20082683L (no) Neuroendokrin tumorbehandling
CY1112907T1 (el) Συνδυασμοι και τροποι χορηγησης θεραπευτικων παραγοντων και θεραπεια συνδυασμου
IL152656A0 (en) Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
ATE422358T1 (de) Kombinationstherapie mittels reovirus und anti- antireovirus antikörpern zur behandlung von ras- vermittelten, proliferativen erkrankungen
TW200744636A (en) Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
CL2011001445A1 (es) Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
PH12022553333A1 (en) Markers for use in methods for treating cancers with antibody drug conjugates (adc)
DE60320398D1 (de) Methoden und medizinische zusammensetzungen zur intravesikalen behandlung von blasenkrebs
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells
JP2014144979A (ja) 治療におけるアポトーシスを増加させるための有糸分裂の阻害剤
ATE381930T1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
JP2008516921A (ja) 多剤耐性の治療および予防
RU2005110536A (ru) Способ лечения рака